Company / Return on Equity (ROE)
Matinas BioPharma Holdings, Inc. Return on Equity (ROE) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-319.5%
FY2024
5-year range
-319.5% / -35.2%
FY2020-FY2024
Trend
-457.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Matinas BioPharma Holdings, Inc. reports negative total equity of -319.5% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-319.5% in FY2024 with a 5-year CAGR of -232.3%.
Declined from -44.4% to -319.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -275.2pp
- 5-Year Change
- -232.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 457.5% year-over-year.
- Peak return on equity (roe) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -319.5% | -457.5% |
| FY2023 | -57.3% | -29.2% |
| FY2022 | -44.4% | +0.0% |
| FY2021 | -44.4% | -25.9% |
| FY2020 | -35.2% | +59.6% |
| FY2019 | -87.3% | +39.8% |
| FY2018 | -145.0% | -13.5% |
| FY2017 | -127.8% | -20.2% |
| FY2016 | -106.3% | +29.4% |
| FY2015 | -150.4% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026